Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Advanced Pharmacodynamic Strategies for Next-Generation Therapies

PROVEN INTELLIGENCE IN PRECLINICAL PHARMACODYNAMICS.

Advanced Pharmacodynamic Strategies for Next-Generation Therapies

CELL & GENE | RNA | BIOLOGICS

Executive Summary

Selecting and validating pharmacodynamic (PD) biomarkers for in vivo next-generation therapies requires a defined strategy, particularly for European regulatory submissions. Key considerations include the distinction between direct and indirect biomarkers, the impact of pre-existing immunity on data interpretation, and the requirements for building a robust data package for an Investigational Medicinal Product Dossier (IMPD). The objective is to generate decision-making data that confirms biological activity and informs dose selection for Advanced Therapy Medicinal Products (ATMPs).

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Frequently Asked Questions

How do you select relevant pharmacodynamic biomarkers for a novel AAV therapy targeting a metabolic disorder?

For Advanced Therapy Medicinal Products (ATMPs) like AAV vectors, biomarker selection is tailored to the mechanism of action. We evaluate both direct evidence of activity (e.g., transgene mRNA expression in target tissues, circulating levels of the therapeutic protein) and indirect, downstream physiological effects (e.g., normalization of a specific metabolite). This dual approach provides a comprehensive view of biological activity for IMPD submissions to agencies like the EMA.

What are the EMA’s expectations for biomarker data in an IMPD submission for a first-in-human trial?

The EMA requires a scientifically justified biomarker strategy that demonstrates proof-of-concept and informs dose selection. The data package should characterize the relationship between dose, exposure, and response. This includes qualified assays to measure target engagement and biological effect in relevant species, providing confidence that the selected starting dose has a high probability of yielding a therapeutic effect.

Can pre-existing neutralizing antibodies (NAbs) affect the interpretation of in vivo PD biomarker data?

Yes, significantly. High NAb titers against a viral vector capsid, such as AAV8 or AAV9, can prevent transduction of target cells, leading to a flat or absent PD biomarker signal. Screening for NAbs before study initiation is a standard part of our process in GxP environments to ensure that pharmacodynamic data accurately reflects the intrinsic activity of the therapeutic candidate.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Defining Efficacy: Pharmacodynamic Biomarkers for ATMPs

A scientifically sound preclinical strategy for an Advanced Therapy Medicinal Product (ATMP) requires robust pharmacodynamic (PD) biomarkers to demonstrate biological activity. These markers serve as quantitative indicators of target engagement and therapeutic effect, forming a foundational component of the data package for regulatory submissions to the EMA. The selection process moves beyond simple presence or absence, focusing on assays that can quantitatively link dose level to a meaningful biological response.

Our approach is to design a tailored biomarker plan that aligns with the specific modality, whether it is an AAV vector delivering a functional gene, an LNP system delivering RNA, or a CRISPR-based gene editing construct. This ensures the generated data is relevant and supports a clear rationale for dose selection in first-in-human studies.

Direct vs. Indirect Evidence of Biological Activity

The most compelling evidence of in vivo efficacy comes from a combination of direct and indirect measurements.

  • Direct Biomarkers: These provide immediate evidence that the therapeutic is functioning as intended. Examples include measuring transgene expression via RT-qPCR or histology techniques like in situ hybridization, or quantifying the restored protein in circulation or target tissues. For a gene therapy targeting dyslipidemia, a direct biomarker would be the measurement of the therapeutic protein itself in plasma samples (PMID: 22505953).

  • Indirect Biomarkers: These measure the downstream physiological consequences of the therapeutic intervention. Following the dyslipidemia example, an indirect biomarker would be the subsequent reduction in circulating LDL-cholesterol or triglycerides. These markers often correlate more closely with the intended clinical outcome.

A comprehensive strategy integrates both types to build a cohesive narrative of efficacy for an IMPD. This is part of the integrated preclinical work that supports our team’s 18-24 month candidate-to-IND timelines. While Franklin Biolabs was formally launched in 2024, this timeline reflects the consistent track record of our founding scientific leadership and core principal scientists, who have maintained a 100% successful IND rate since 2019.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

Confounding Factors: The Role of Pre-existing Immunity

Interpreting PD biomarker data requires an understanding of potential biological confounders, particularly pre-existing immunity to viral vectors. The presence of neutralizing antibodies (NAbs) against AAV capsids can block vector entry into target cells, completely abrogating the therapeutic effect and preventing any measurable response in PD assays (PMID: 26067568).

Screening nonhuman primate models for pre-existing NAbs against the specific clinical capsid (e.g., AAV5, AAV9) is a standard component of robust study design. This ensures that any lack of efficacy observed is due to the intrinsic properties of the ATMP, not a pre-existing immune block. This level of scientific diligence is foundational to our work in our >100,000 sq ft of dedicated animal facility and laboratory space.

This rigorous approach to preclinical study design and execution is central to the services provided by our team. For more information on our overall capabilities, please see our main services page.
Preclinical | Translational Services

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities